about
Inhibition of the Prokaryotic Pentameric Ligand-Gated Ion Channel ELIC by Divalent CationsGABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.Curcumol allosterically modulates GABA(A) receptors in a manner distinct from benzodiazepines.Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Isoliquiritigenin, a chalcone compound, enhances spontaneous inhibitory postsynaptic response.Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's Diseaseα2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.Functional properties of GABA synaptic inputs onto GABA neurons in monkey prefrontal cortexIdentification of GABA A receptor modulators in Kadsura longipedunculata and assignment of absolute configurations by quantum-chemical ECD calculationsAnxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes.Current diagnosis and treatment of anxiety disorders.Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophreniaDeregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease.Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors.Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic EfficacyMice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists.Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease.Diazepam treatment blocks the elevation of hippocampal activity and the accelerated proliferation of hippocampal neural stem cells after focal cerebral ischemia in mice.A functional SNP catalog of overlapping miRNA-binding sites in genes implicated in prion disease and other neurodegenerative disorders.Depressive effects on the central nervous system and underlying mechanism of the enzymatic extract and its phlorotannin-rich fraction from Ecklonia cava edible brown seaweed.Guanosine Anxiolytic-Like Effect Involves Adenosinergic and Glutamatergic Neurotransmitter Systems.Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.
P2860
Q27675268-29865F56-7D07-4F75-A401-24C391447073Q30421260-68FA183D-69F0-4B11-8BCB-34D9EDCDC83FQ30466591-3FF3BD48-6694-40B2-8518-E532EEFC0063Q33594728-F4F504EE-1031-420A-B746-0CDAE061F65EQ33659830-F4BBE3EF-0C9F-4A45-B0B8-09FFDACC524FQ33787347-7D236FFD-84B1-4095-AB4F-4E2A1D0E5C6FQ33813021-9FE5CDC7-BE7F-4853-82A7-EF1E8583D5A5Q34295813-0BE9169B-06EF-436F-A2B6-B1D5138CB250Q35015325-C249509B-A7DD-4D52-A664-35896482910DQ35178490-EFBC4544-E755-410D-9D54-477F0E8596DEQ35447941-A132AF2B-E5C4-4840-98E4-A182867CD803Q35924378-2EED61CD-D939-4F82-8BD4-44E94F85C837Q36771550-5C33DD86-1A9A-4455-A129-31A4DEFE7BACQ37670034-333AB762-72F6-4001-859A-4E6ABE6724C5Q37929602-BC6571CF-006A-4CA5-9124-808D59F688F4Q38106483-2947159D-6733-4B14-AD26-8E3828EE3E39Q38820230-605327C8-8EFB-4AA0-8249-B0A24C303BEEQ40819756-BA81CA58-4EC3-46AD-9CE2-32D70B5D5CDAQ41876109-0A43AFDF-BF54-40FB-A252-58A765E7CBDEQ43427045-165D3B34-970D-4935-B780-72C70AC9D44BQ43756240-B5EE7FA5-0E78-4F8C-87A6-C05FC283344FQ47990584-09877A9E-7396-468B-8F3D-BFDDCB36F694Q48264995-C081AFB4-ADB3-4022-A042-64DAB362CB46Q49029414-A84A9C88-3FC3-4464-B590-F7524D38DE0EQ49256155-52E514D1-3B48-4069-B444-365D5AD78EF5
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The rise of a new GABA pharmacology.
@ast
The rise of a new GABA pharmacology.
@en
The rise of a new GABA pharmacology.
@nl
type
label
The rise of a new GABA pharmacology.
@ast
The rise of a new GABA pharmacology.
@en
The rise of a new GABA pharmacology.
@nl
prefLabel
The rise of a new GABA pharmacology.
@ast
The rise of a new GABA pharmacology.
@en
The rise of a new GABA pharmacology.
@nl
P1433
P1476
The rise of a new GABA pharmacology.
@en
P2093
Hanns Möhler
P304
P356
10.1016/J.NEUROPHARM.2010.10.020
P577
2010-10-28T00:00:00Z